In a randomized comparison for r/r metastatic melanoma, the addition of a COX-2 inhibitor for inflammation control to metronomic low-dose chemotherapy emerged significantly inferior compared to intensified anti-inflammatory therapy with COX-2 inhibitor plus pioglitazone concerning PFS (Table 3) (38, 135). Here, PTGS2 is linked to metastatic melanoma.